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Abstract
Background: Cardiovascular disease has become a major health problem, and it has been associated with both
environmental and genetic factors. Studies have shown that the Mediterranean Diet (MeDiet), or its components
such as nuts and olive oil, may be strongly associated with the improvement of cardiovascular risk factors in
specific populations. The purpose of the GENUTRI study is to investigate the interaction of genetics with
cardiovascular risk factors in a non-Mediterranean population with coronary artery disease (CAD) according to three
different diets: rich in pecan nuts, in extra-virgin olive oil or a control diet.
Methods/design: The GENUTRI study is a single-center, randomized, open-label, parallel-group, 12-week pragmatic
clinical trial conducted in patients aged 40 to 80 years and diagnosed with CAD. A standardized questionnaire
will be applied to data collection and a blood sample will be obtained for lipid, glycemic and inflammatory
profile evaluation. Polymorphisms in the CD36 and STAT3 genes will be detected using the TaqMan® SNP
Genotyping Assay. Patients will be allocated in three groups: group 1: 30 g/day of pecan nuts; group 2: 30 ml/day
of olive oil; and group 3: control diet. The primary outcome will consist of changes in LDL-cholesterol (in mg/dl)
after 12 weeks of intervention.
Discussion: Studies have shown the beneficial effects of diets rich in nuts and olive oil mainly in the
Mediterranean population. GENUTRI is a clinical trial focusing on the effects of nuts or olive oil
supplementation in Brazilian individuals. Additionally, we will try to demonstrate that genetic polymorphisms
linked to cardiovascular disease may modulate the effects of different diets on biochemical and inflammatory
markers among these subjects.
Trial registration: ClinicalTrials.gov Identifier: NCT02202265 (registered on 18 July 2014: first version).
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Background
According to the World Health Organization (WHO),
cardiovascular disease is the leading cause of mortality
worldwide, being responsible for 18 million deaths annu-
ally [1]. Coronary artery disease (CAD) is considered the
main cardiovascular disorder, and approximately 46 % of
the cardiovascular mortality in men and 38 % in women
is attributed to CAD [2].
About 80 % of all mortality from cardiovascular disor-
ders could be prevented if obesity, unhealthy diet and
physical inactivity were excluded from the general popu-
lation [3] and the adherence to a higher-quality diet is
associated with decreased mortality risk [4]. In this
meaning, the Mediterranean Diet (MeDiet), which incor-
porates the traditional healthy living habits of people
from countries bordering the Mediterranean Sea, has
been consolidated as a dietary pattern highly associated
with reduced cardiovascular [5] and mortality risk [6].
Besides, adherence to a MeDiet pattern seems to be
strongly related to cardiovascular protection when com-
pared to low-fat dietary patterns [5, 7].
Nuts (rich in polyunsaturated fatty acids – PUFA) and
olive oil (rich in monounsaturated fatty acids – MUFA)
are highly used in the Mediterranean cuisine [8]. Despite
regular intake of nuts and olive oil seems to be inversely
associated with cardiovascular risk factors, CAD and
mortality in some populations [9–11], these effects have
not been observed in all studies, mainly in non-
Mediterranean countries [12, 13]. The PREDIMED
(PREvención con DIeta MEDiterránea) study was a lar-
ger clinical trial that randomly assigned participants who
were at high cardiovascular risk (but with no cardiovas-
cular disease) to one of three diets: a MeDiet supple-
mented with extra-virgin olive oil (minimum 50 ml/day)
or with mixed nuts (30 g/day), or a control diet (low-fat
diet). The PREDIMED study showed that both MeDiets
supplemented with extra-virgin olive oil or nuts reduced,
by approximately 30 %, the incidence of major cardio-
vascular events in a European population [5].
Beyond unhealthy diet, genetic factors are strongly
associated with the development and the progression of
cardiovascular diseases [14]. The CD36 (CD36 molecule
(thrombospondin receptor)) and the STAT3 (signal
transducer and activator of transcription 3 (acute-phase
response factor)) genes are both related to pathways
involved in the genesis of CAD [15, 16], and may inter-
act with dietary factors. The single-nucleotide poly-
morphism (SNP) rs1761667 G>A in the CD36 gene has
been associated with a higher intake of dietary fats and
obesity [17], and the SNP rs8069645 A>G in the STAT3
gene seems to interact with higher saturated fat intake
and increases the risk for abdominal obesity [18]. How-
ever, the association of these SNPs with cardiovascular
risk factors, such as lipid profile and inflammatory
markers, and a possible interaction with different dietary
fats are poorly understood in patients with CAD.
Therefore, we design a randomized clinical trial to in-
vestigate the interaction of genetics with cardiovascular
risk factors in subjects with CAD who do not live in the
Mediterranean region, according to dietary prescription
with different supplementary fats used in the MeDiet.
Methods/design
Study design and centers
The GENUTRI study is a single-center, randomized,
open-label, parallel-group, 12-week pragmatic clinical
trial (blinded outcome assessment). The study popula-
tion will include patients with the diagnosis of CAD
identified during a period of hospitalization in the
Institute of Cardiology of Rio Grande do Sul (IC/FUC),
Brazil, and outpatients who volunteered for the trial.
The randomization, allocation and follow-up procedures
will take place at the outpatient Clinic of Nutrition.
Study objectives
The primary objective of this randomized-controlled
clinical trial is to evaluate the effect of three dietary
approaches on metabolic, inflammatory and anthropo-
metric profiles in patients with CAD after 12 weeks. The
secondary objective is to detect an interaction of
patients’ response to these three dietary approaches with
polymorphisms in the CD36 and STAT3 genes.
Participants
Inclusion criteria: patients aged 40–80 years diagnosed
with CAD who have signed an informed consent to
participate. CAD was defined by a diagnosis of previous
myocardial infarction, acute coronary syndrome or typ-
ical angina pectoris. Myocardial infarction was defined
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according to the universal definition of myocardial
infarction [19].
Exclusion criteria: psychiatric disease; morbid obesity
(body mass index (BMI) ≥40 mg/m2); expectancy of life less
than 6 months; pregnancy or lactation; renal failure (in dia-
lysis); congestive heart failure; prior organ transplantation;
uncontrolled hypo/hyperthyroidism; wheelchair-dependant
individuals; use of vitamin/nutritional supplements; chronic
use of nonsteroidal anti-inflammatory drugs; and concomi-
tant participation in another experimental study.
Ethical aspects
All procedures will be conducted in accordance with the
ethical standards for human subject research set forth in
the Declaration of Helsinki and also with the Good
Clinical Practice (GCP) guidelines [20]. Written in-
formed consent will be obtained by researchers from all
patients included in the trial. The project was approved
by the Research Ethics Committee of the Institute of
Cardiology (registration number UP. 4861.13) and is reg-
istered in the ClinicalTrials.gov database.
Study protocol
Patients with CAD who have been hospitalized in our in-
stitution and/or those submitted to coronary interventions
for CAD will be invited by telephone calls to participate in
the study. For the individuals who meet the inclusion cri-
teria and are eligible for the trial, an appointment will be
scheduled with the researchers’ staff (physicians and nutri-
tionists). Voluntary individuals who contact the investiga-
tors and who meet the inclusion criteria will be also
scheduled. All individuals will be advised by telephone to
fast overnight for 8 hours before the meeting.
After checking all exclusion criteria and signing the in-
formed consent, a blood sample will be collected and the
subjects will undergo a baseline cardiology assessment. A
structured questionnaire containing demographic, socio-
economic and educational data will be administered.
Medical history (including previous outcomes and drug
prescriptions) and behavior data, such as smoking, alcohol
intake and level of physical activity will be collected. Blood
pressure levels will be evaluated; anthropometric data
(weigh, height, waist, hip and neck circumferences) and re-
cords about actual dietetic consumption will be assessed.
After randomization and once allocation has been
completed, the patient will be appropriately advised
according to the intervention designated: pecan nut
supplementation diet, olive oil supplementation diet or a
control diet. Patients will be followed for a period of
3 months (12 weeks), and follow-up visits will be scheduled
at 30 days, 60 days and 90 days (final appointment), when
blood will be collected for laboratory analyses. Figure 1
shows all procedures and its periodicity during the trial
according to follow-up visits. The patients will be
reminded and prompted regarding the follow-up visits and
the interventions by telephone calls.
Randomization and blinding
The randomization sequence (in blocks) will be
computer-generated using the http://www.randomiza-
tion.com/ website, and then organized in sealed opaque
envelopes. After fulfilling the eligibility criteria during the
first visit, participants will be randomly assigned by inde-
pendent investigators to one of the three diet groups in
accordance with the generated randomization list. Both
patients and investigators responsible for evaluation and
Fig. 1 Flow chart of the GENUTRI study
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data collection will be aware of the assigned diet. The staff
involved in the biochemical outcomes’ evaluation and in
the statistical analysis will be blinded to group allocation.
Interventions
All individuals will receive individual dietary advice ac-
cording to their specific caloric needs (to maintain or to
lose weight) despite treatment group, and the following
recommendations will be used to calculate the total daily
calories: to weight management: 25 kcal/kg/day; to
weight loss: 20 kcal/kg/day [21]. The individual distribu-
tion of macronutrients (dietary carbohydrates, protein
and fats), independent of the group allocated, will be
determined and calculated according to Brazilian guide-
lines for dyslipidemia [22], metabolic syndrome [21],
hypertension [23] and diabetes [24].
Group 1 (nut supplementation, NS) will receive, in
addition to dietary prescription, 1 kg of pecan nuts ad-
equately packed for 30 days of treatment (approximately
900 g, considering an intake of 30 g/day [25]) plus
educational materials concerning the adequate ingestion
and storage of the nuts. Patients will be counseled about
not consuming olive oil during the treatment. Group 2
(olive oil supplementation, OS) will receive, in addition
to dietary prescription, 1 liter of extra-virgin olive oil ad-
equately packed for 30 days of treatment (approximately
900 ml, considering an intake of 30 ml/day [25]) plus
educational materials concerning the adequate ingestion
and maintenance of the olive oil. Patients will be advised
to not consume mixed nuts and oilseeds during the
study period. Group 3 (control diet, CD) will receive
standard dietary advice according to Brazilian guidelines
[21–24] and will be discouraged from using olive oil,
nuts and oilseeds during this period.
Assessment tools and variables
Demographic variables
A structured questionnaire will be administered to all
participants for collection of demographic parameters
(age, sex, ethnicity), socioeconomic and educational data.
Genetic data
Deoxyribonucleic acid (DNA) will be isolated from a
5-ml venous blood sample by means of a specific toolkit
according to the manufacturer’s instructions. The detec-
tion of polymorphisms and genotype characterization
will be performed from frozen blood samples at −80 °C
by means of the TaqMan® SNP Genotyping Assay
according to the manufacturer’s instructions and to the
available protocol. For each gene, a different genotyping
assay kit will be used: ID C_30301828_10 to detect the
G allele in rs8069645 STAT3 and ID C_ 8314999_10 to
detect the A allele in rs1761667 CD36.
Clinical and behavioral variables
Medical history: data on CAD specifications, history of
present illness, past medical history, history of previous
outcomes (i.e., heart attack and stroke) and current
medications will be collected during the patient inter-
view. Hypertension, type-2 diabetes mellitus and dyslip-
idemia will be considered present according to previous
diagnosis and/or the use of medications to treat each of
these conditions.
Blood pressure: systolic and diastolic blood pressure
will be evaluated using an automatic validated monitor-
ing device (OMRON® HEM-7200) with an adequately
sized cuff to the arm circumference, according to the
guidelines [23].
Body weight and height: weight (kg) will be measured
with participants barefoot, wearing minimal clothing,
and standing at the center of a digital platform scale;
height (cm) will be obtained with participants barefoot
in the standing position, and with both arms hanging
freely at the side with palms facing thighs.
Waist, hip and neck circumferences: waist circumfer-
ence (cm) will be obtained with a plastic, flexible meas-
uring tape at the middle point between the lower costal
margin and the iliac crest in a perpendicular plane, with
the patient standing on both feet, approximately 20 cm
apart, and with both arms hanging freely. Hip circumfer-
ence will be measured at the level of the widest circum-
ference over the buttocks with the research assistant
kneeling at the side of the participant, so that the level
of maximum extension can be seen. Neck circumference
(cm) will be measured with the head straight and eyes
staring forward, horizontally, 1 inch above the laryngeal
prominence.
Smoking and alcohol intake: smoking will be defined as
a categorical variable (never, current or past smoking) and
excessive alcohol intake will be detected if participants
have a consumption of 30 g or more and 15 g or more of
ethanol a day for men and women, respectively [26].
Dietary evaluation: food intake will be evaluated by
means of 24-h dietary recalls (24-HDRs). Caloric intake
and nutrients will be estimated by Avanutri Revolution®
Nutritional Evaluation software (Rio de Janeiro, Brazil) [27].
Physical activity: levels of physical activity will be eval-
uated according to the International Physical Activity
Questionnaire (IPAQ) short version [28] translated and
validated into the Portuguese language.
Laboratory variables
Blood samples will be collected by a trained professional
at baseline and after 12 weeks. Samples will be centri-
fuged at 22 °C, 2000 rpm, for 10 min and stored in
Eppendorf tubes at −80 °C for later analysis.
Lipid profile: total cholesterol, low-density lipoprotein
cholesterol (LDL-c) and serum triglycerides will be
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evaluated by the enzymatic colorimetric method; high-
density lipoprotein cholesterol (HDL-c) will be evaluated
by the immunoprecipitation method (Roche Modular P
Chemistry Analyzer®).
Inflammatory profile: interleukin-6 (IL-6), interleukin-
10 (IL-10) and tumor necrosis factor alpha (TNF-α) will
be evaluated by enzyme-linked immunosorbent assay
(ELISA) using commercial kits (R&D Systems, Inc.,
Minneapolis, MN, USA), and according to the manufac-
turer’s instructions in a spectrophotometer (SpectraMax
M2®). High-sensitivity C-reactive protein (hs-CRP) will
be evaluated by the turbidimetric technique (Roche
Cobas Integra 400 Plus Chemistry Analyzer®). Fibrinogen
will be evaluated by the coagulometric method (Sysmex
CA-600 systems®).
Glycemic profile: fasting glucose will be evaluated by
the enzymatic colorimetric method (Roche Modular P
Chemistry Analyzer®). Glycated hemoglobin will be
evaluated by the immunoturbidimetric method (Roche
Cobas Integra 400 Plus Chemistry Analyzer®). Serum
insulin will be evaluated by electrochemiluminescence
technique (Roche Elecsys 2010 Immunoassay Analyzer®).
Outcome measures
Primary outcome
The primary outcome measure will consist of changes in
LDL-c (mg/dl) from baseline to 12 weeks.
Secondary outcomes
 Changes in other lipid measures (total cholesterol,
HDL-c, serum triglycerides) and inflammatory
profiles (hs-CRP, IL-6, IL-10 and TNF-α) from
baseline to 12 weeks.
 Changes in glycemic profile (fasting glucose, serum
insulin and glycated hemoglobin), anthropometric
indexes (weight, BMI and waist and neck
circumferences) and in systolic and diastolic blood
pressure from baseline to 12 weeks.
Patients will be prompted to complete the follow-up; if
this is not possible, a 12-week visit will be scheduled for
blood collection and measurements of primary and
secondary outcome variables.
Sample size
Sample size calculation was carried out in the WinPepi
11.20 for Windows program (Brixton Health, Israel). We
used the data reported by Casas et al. [9], which assessed
the effectiveness of a Mediterranean Diet pattern com-
pared to a control diet among 164 individuals at high
risk for cardiovascular disease. For a significance level of
α = 0.05 and a statistical power of 80 %, with a between-
group difference corresponding to a reduction of 13 mg/
dl in the primary outcome (LDL-c) and considering no
differences between olive oil and nut diets, the minimum
sample size would be 171 patients (57 randomized to
each group). Considering an expected loss rate of 20 % of
patients, the total sample size needed will be 204 patients.
The allele frequency of the rs1761667 G>A and
rs8069645 A>G SNPs in a Brazilian population is
unknown. Since, in other studies, a frequency of
approximately 40 % for each allele (A and G) has been
found [23, 24], we expect that 204 individuals will
provide a statistical power of 95 % in this analysis.
Statistical analyses
All data will be double-checked prior to statistical
analyses. Baseline demographic and clinical characteristics
of the participants according to groups will be analyzed
using descriptive statistics, and inferential statistics will be
employed to compare the effects of the dietary interven-
tions on the different outcome measures. Continuous vari-
ables following a normal distribution will be expressed as
mean ± standard deviation and asymmetrically distributed
continuous variables will be expressed as median and
interquartile range. Categorical variables will be expressed
as absolute and relative frequencies. Departure of geno-
type distributions from the Hardy-Weinberg equilibrium
in all participants will be assessed using chi-square tests.
For between-group comparisons, analysis of variance
(ANOVA) and the Kruskal-Wallis H test will be used for
variables with normal and asymmetric distribution,
respectively. The chi-square or Fisher’s exact tests will be
used to evaluate categorical variables. All relevant
endpoints (new cardiovascular events and death) will be
registered as absolute number and percentages according
to groups. The generalized estimating equations (GEE)
model under the missing-at-random assumption will be
used for comparison between outcome variables during
the study period. Delta from all outcome data will be ob-
tained from the difference between the measure at
12 weeks and baseline, and will be compared according to
groups using analysis of covariance (ANCOVA), adjusted
for potential confounders (for instance, differences in
baseline data). The SNPs will be included in all ANCOVA
models as interaction variables. There is no interim ana-
lysis planned. The significance level will be set at 5 %, and
all data will be analyzed in SPSS 18.0 (SPSS Inc., Chicago,
IL, USA) according to intention-to-treat.
Discussion
As previously described, the PREDIMED study showed
that a MeDiet supplemented with mixed nuts (walnuts,
almonds and hazelnuts) or olive oil reduces the incidence
of major cardiovascular events in patients at high cardio-
vascular risk [5]. The PREDIMED study was conducted in
Spain; in our study, instead of a classical MeDiet,
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participants receive a meal plan according to their daily
caloric needs (maintenance or reduction of body weight),
based on Brazilian guidelines [21–24], and all supplements
used in our protocol (olive oil and pecan nuts) are
supplied by local producers from southern Brazil. Besides,
the amount of daily olive oil prescribed (30 ml/day) to our
participants is lower than PREDIMED study, and it was
adapted to the dietary habits of Brazilian individuals, who
are not used to ingesting very large quantities of olive oil.
It is known that there may be some variations in the
chemical composition of olive oil and nuts according to
the geographical area where they are grown. Luna et al.
[29] evaluated 39 samples of olive oil from eight produ-
cing countries; all olive trees were grown under the same
conditions and the fruits were harvested at the same
stage of maturation. Although the oil was extracted
through the same process, these authors identified about
64 different volatile compounds, showing that the
geographical area of the olive tree cultivation may be
responsible for specific characteristics of olive oil, which
could reflect on its beneficial effects [29, 30].
In our study, we are using a Spanish variety of olive oil
(Arbequina), one that is also cultivated and produced in
southern Brazil. A recent study showed that Brazilian olive
oils have a high content of phenolic compounds, levels that
are comparable to those in olive oils produced in other
countries [31]. Noteworthy is the fact that beyond olive oil,
the chemical composition of unsaturated fatty acids from
pecan nuts is also influenced by its place of cultivation [32].
Although American, European and Asian clinical trials
have shown consistent interactions between genetic
polymorphisms, diets and the modulation of biochem-
ical cardiovascular markers, there are few reports from
Brazilian individuals. Barcelos et al. [33], for instance,
showed that the -278A>C (rs3808607) polymorphism in
the CYP7A1 gene can modify serum triglyceride concen-
trations in response to a reduced fat diet in a dyslipid-
emic male population; in other study, the consumption
of 1 unit of Brazil nuts a day increased the selenium
status and the glutathione peroxidase-1 (GPx1) activity
in obese women, regardless of the GPx1 Pro198Leu
polymorphism [34]. The Brazilian population is consid-
ered one of the most ethnically mixed in the world [35],
and this must be considered before all interpretations
regarding genetic studies. In populations in which the
substructure created by inter-ethnic cross further
increases the fluidity of racial and/or ethnic labels,
extrapolation of nutrigenetic data from well-defined
ethnic groups should be made with caution. To impact
positively on global health, nutrigenomics must broaden
its scope of investigation with respect to both target and
population diversity, to avoid the risk of contributing to
the creation of a genomics that is divided between
regions and nations.
The randomized controlled GENUTRI trial is designed
to explore three different dietary approaches for cardio-
metabolic and inflammatory profile improvement in
patients with established CAD. The dietary approaches
suggested by the Brazilian guidelines for individuals at
very high cardiovascular risk are largely recommended in
our country, and consist of 50–60 % of dairy energy from
carbohydrates, 10–15 % from proteins, 25–35 % from
total fats, <7 % from saturated fatty acids (SFA), <20 %
from MUFA, <10 % from PUFA, <1 % from trans fats,
<200 mg/day from dietary cholesterol, 20–30 g/day from
fiber and <2400 mg/day of sodium [21–24]. In Brazil, the
effects of a modified MeDiet were evaluated by only one
small study with 40 CAD patients, with mixed and incon-
sistent results [36]. The GENUTRI study is the first ad-
equately powered clinical trial focusing on nuts or olive oil
supplementation in a southern Brazilian population. Since
it may be difficult for Brazilian individuals to adhere to
and maintain a traditional MeDiet pattern, the study
findings will have important implications not only for our
population but also for the feasibility of other potential
applications for the long-term prescription of cardiopro-
tective foods in individuals with CAD. Additionally, we
will try to demonstrate that genetic polymorphisms linked
to cardiovascular disease may modulate the effects of
different diets on biochemical and inflammatory markers.
A large randomized clinical trial has been recently
proposed in patients with CAD based on novel dietary
interventions with the potential for low cost and high
feasibility for use in Brazil [37]. However, this protocol
does not consider genetic differences regarding the
interbred Brazilian population. The GENUTRI trial aims
also to stimulate the consumption of local foods since
the olive oil and pecan nuts provided in the study are
cultivated and produced in our country by farmers on a
small scale. If effective, it may contribute to economic
growth in southern Brazil by encouraging the consump-
tion of these foods. Besides, our results may generate
hypotheses for larger randomized clinical trials regarding
nutrigenetic approaches in different Brazilian regions.
In conclusion, although many studies have demon-
strated the beneficial effects of the MeDiet and/or diet-
ary intake of olive oil and nuts on cardiometabolic and
inflammatory markers, clinical trials evaluating these
foods in Brazilian/non-Mediterranean populations with
CAD are scarce. Besides, the assessment of specific gen-
etic polymorphisms may help to understand the individ-
ual different responses to specific dietary intervention.
Trial status
The trial is ongoing. One hundred and twenty patients
have completed the study protocol and additional
patients are being recruited. The results of the study will
be communicated to all participants.
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